Researchers in Brazil have identified a molecule in the venom of the Amazonian scorpion Brotheas amazonicus that kills breast cancer cells in vitro with effects similar to the chemotherapy drug paclitaxel, according to FAPESP. Early tests indicate the peptide chiefly induces necrosis, underscoring venoms’ promise as a source of biopharmaceuticals.
Scientists at the University of São Paulo’s Ribeirão Preto School of Pharmaceutical Sciences (FCFRP‑USP), working with the National Institute for Amazonian Research (INPA) and Amazonas State University (UEA), isolated a venom‑derived peptide named BamazScplp1 from the scorpion Brotheas amazonicus. In cell‑culture experiments, the compound’s impact on breast cancer cells was comparable to paclitaxel and appeared to kill cells mainly by necrosis, FAPESP reported.
The preliminary findings were presented at FAPESP Week France, held June 10–12, 2025, in Toulouse, capital of the Occitanie region. Project coordinator Eliane Candiani Arantes of FCFRP‑USP said bioprospecting guided the identification of the molecule and its activity against breast cancer cells, according to FAPESP.
The work builds on FAPESP‑supported efforts to clone and express bioactive molecules at the Center for Translational Science and Development of Biopharmaceuticals (CTS), based at the Center for the Study of Venoms and Venomous Animals (CEVAP) at São Paulo State University (UNESP) in Botucatu. As part of this broader program, researchers also identified two scorpion‑venom neurotoxins with immunosuppressive effects, the agency said.
Next steps include producing BamazScplp1 and related molecules via heterologous expression to enable larger‑scale studies. The group has used yeasts such as Pichia pastoris for similar venom proteins and says it aims to apply the approach here as well.
Breast cancer is the most commonly diagnosed cancer among women worldwide and a leading cause of cancer death in women, underscoring the need for new therapeutic strategies. The current results are limited to laboratory tests; further research will be required to assess safety and efficacy beyond the dish.
